Tech Company Financing Transactions
Tissium Funding Round
On 5/23/2023, Tissium raised $50 million in Series D funding from Cathay Health, Credit Mutuel Equity and Fonds Stratégique des Transitions.
Transaction Overview
Company Name
Announced On
5/23/2023
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to finance its commercial launch and platform extension. The financing will allow Tissium to continue to execute on its development plan, funding the company for the commercialisation of its first products in nerve and hernia repair and fueling the extension of its pipeline of products and its platform.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
74 rue du Faubourg Saint-Antoine
Paris, 75012
FR
Paris, 75012
FR
Phone
Website
Email Address
Overview
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christophe Bancel
Chief Financial Officer
Romain Attard
Co-Founder
Maria Pereira
Browse more venture capital transactions:
Prev: 5/23/2023: Ballerine venture capital transaction
Next: 5/23/2023: Nue.io venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs